Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  • STATUS
    Recruiting
  • End date
    Mar 1, 2024
  • participants needed
    987
  • sponsor
    National Cancer Institute (NCI)
Send
Updated on 17 January 2021
See if I qualify
Investigator
Joseph M. Wiley
Primary Contact
Sinai Hospital of Baltimore (7.7 mi away) Contact
+440 other location
ct scan
estimated creatinine clearance
cancer
corticosteroids
hysterectomy
lymphoma
immunosuppressive
monoclonal antibodies
prednisone
human immunodeficiency virus
measurable disease
hepatitis
cell transplantation
gilbert's syndrome
doxorubicin
combination chemotherapy
tumor cells
positron emission tomography
nivolumab
alopecia
pegfilgrastim
dacarbazine
vinblastine
topical steroids
hypothyroidism
positron emission tomography/computed tomography
brentuximab
classical hodgkin lymphoma
mixed cellularity hodgkin lymphoma

Summary

This randomized phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.

Description

PRIMARY OBJECTIVES:

I. To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin hydrochloride [doxorubicin], vinblastine sulfate [vinblastine], dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine).

SECONDARY OBJECTIVES:

I. To compare overall survival (OS) in patients randomized to N-AVD versus BV-AVD.

II. To compare event-free survival (EFS) in patients randomized to N-AVD versus BV-AVD.

III. To compare the metabolic complete response (CR) rate at the end of treatment in patients randomized to N-AVD versus BV-AVD.

IV. To compare the physician-reported treatment-related adverse event rates between arms stratified by age groups.

V. To compare patient-reported symptoms using selected Patient Reported Outcome Common Toxicity Criteria for Adverse Events (PRO-CTCAE) items between arms stratified by age groups.

VI. To compare the safety and tolerability of N-AVD versus that of BV-AVD.

QUALITY OF LIFE OBJECTIVES:

I. To compare between arms patient-reported fatigue, neuropathy and health-related quality of life over time (baseline, beginning of cycle 3, 4-8 weeks after completion of treatment, and 1 and 3 years after randomization) using the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), and the PROMIS Global, respectively.

BANKING OBJECTIVES:

I. To bank specimens for future correlative studies. II. To bank positron emission tomography (PET)-computed tomography (CT) images for future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim subcutaneously (SC) on days 2 and 16, or filgrastim SC or IV on days 5-10 and 20-25 for adults or days 4-9 for pediatric patients. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician.

ARM II: Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 5-10 and 20-25 for adults or days 4-9 for pediatric patients. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician.

After completion of study treatment and prior to disease progression, patients are followed up every 3 months for the first year, every 6 months for years 2 and 3, then annually until 10 years after registration. Patients are followed up at the time of progression and then annually until 10 years after registration. Patients who receive radiation therapy are followed up at 8-12 weeks after completion of radiation therapy.

Details
Treatment radiation therapy, questionnaire administration, filgrastim, quality-of-life assessment, doxorubicin hydrochloride, doxorubicin, Nivolumab, pegfilgrastim, dacarbazine, vinblastine sulfate, brentuximab vedotin, Vinblastine
Clinical Study IdentifierNCT03907488
SponsorNational Cancer Institute (NCI)
Last Modified on17 January 2021

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

 Yes No Not Sure

Inclusion Criteria

Do you have any of these conditions: Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma or Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma or Lymphocyte-Rich C...?
Do you have any of these conditions: Classic Hodgkin Lymphoma or Ann Arbor Stage III Hodgkin Lymphoma or Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma or Lymphocyte-Rich...?
Do you have any of these conditions: Ann Arbor Stage IVA Hodgkin Lymphoma or Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma or Classical Hodgkin Lymphoma or Ann Arbor Stag...?
Do you have any of these conditions: Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma or Ann Arbor Stage IVA Hodgkin Lymphoma or Ann Arbor Stage IV Mixed Cellularity Classic...?
Do you have any of these conditions: Ann Arbor Stage IIIB Hodgkin Lymphoma or Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma or Ann Arbor Stage III Nodular Sclerosis Clas...?
Do you have any of these conditions: Ann Arbor Stage III Hodgkin Lymphoma or Ann Arbor Stage IIIA Hodgkin Lymphoma or Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma or Lym...?
Do you have any of these conditions: Ann Arbor Stage IIIB Hodgkin Lymphoma or Ann Arbor Stage IVB Hodgkin Lymphoma or Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma or Ann...?
Do you have any of these conditions: Classical Hodgkin Lymphoma or Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma or Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin ...?
Do you have any of these conditions: Ann Arbor Stage IVB Hodgkin Lymphoma or Ann Arbor Stage IIIA Hodgkin Lymphoma or Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma or Ann ...?
Do you have any of these conditions: Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma or Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma or Ann Arbor Stage III ...?
Is your age greater than or equal to 12 yrs?
Do you have any of these conditions: Ann Arbor Stage III Hodgkin Lymphoma or Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma or Ann Arbor Stage III Nodular Sclerosis Classic...?
Do you have any of these conditions: Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma or Ann Arbor Stage IIIB Hodgkin Lymphoma or Ann Arbor Stage IV Mixed Cellularity Class...?
Do you have any of these conditions: Ann Arbor Stage IVA Hodgkin Lymphoma or Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma or Classic Hodgkin Lymphoma or Ann Arbor Stage I...?
Do you have any of these conditions: Ann Arbor Stage IIIA Hodgkin Lymphoma or Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma or Ann Arbor Stage IV Hodgkin Lymphoma or Ann A...?
Do you have any of these conditions: Ann Arbor Stage IIIB Hodgkin Lymphoma or Classical Hodgkin Lymphoma or Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma or Ann Arbor Sta...?
Do you have any of these conditions: Lymphocyte-Rich Classic Hodgkin Lymphoma or Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma or Ann Arbor Stage IV Nodular Sclerosis Cl...?
Do you have any of these conditions: Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma or Ann Arbor Stage III Hodgkin Lymphoma or Ann Arbor Stage IVA Hodgkin Lymphoma or Ann A...?
Do you have any of these conditions: Ann Arbor Stage IVB Hodgkin Lymphoma or Ann Arbor Stage IVA Hodgkin Lymphoma or Ann Arbor Stage III Hodgkin Lymphoma or Ann Arbor Stage IV Hodgkin Lym...?
Gender: Male or Female
All patients must have histologically confirmed newly diagnosed, previously untreated stage III or IV classical Hodgkin lymphoma (nodular sclerosing, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified [NOS]). Nodular lymphocyte predominant Hodgkin lymphoma is not eligible
Patients must have bidimensionally measurable disease (at least one lesion with longest diameter >= 1.5 cm) documented on the Lymphoma Baseline Tumor Assessment Form in Rave
Patients must have a whole body or limited whole body PET-CT scan performed within 42 days prior to registration. (A contrast-enhanced [diagnostic] CT, magnetic resonance imaging [MRI] or MRI-PET is acceptable in event that PET-CT is contraindicated, however the same modality must be utilized through the trial.) NOTE: All images from PET-CT, CT, MRI or MR-PET scans performed as standard of care to assess disease (within 42 days prior to registration) must be submitted and associated radiology reports must be submitted
Patients must not have received any prior chemotherapy, radiation, or antibody-based treatment for classical Hodgkin lymphoma. Steroid pre-treatment is permitted
Patients must not have had prior solid organ transplant
Patients must not have had prior allogeneic stem cell transplantation
Patients must not have received a live vaccine within 30 days prior to planned day 1 of protocol therapy (e.g. measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette-Guerin [BCG], oral polio vaccine, and oral typhoid)
At registration, investigator must declare intent-to-treat with residual PET radiation therapy (residual PET RT- RPRT) to be administered after patient completes 6 cycles of therapy if, after end of treatment, the patient meets criteria specified for receiving RT). Patients will be stratified by investigator's intent-to-treat with residual PET RT
All patients enrolled by Children's Oncology Group (COG) investigators will be considered intent-to-treat with residual PET RT
Patients must have a performance status corresponding to Zubrod scores of 0, 1 or 2. Use Lansky for patients =< 17 years of age. The conversion of the Lansky to Eastern Cooperative Oncology Group (ECOG) scales is intended for National Cancer Institute (NCI) reporting purposes only
Adults (age 18 or older): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight
Pediatric Patients (age 12-17), the following must have been obtained within
days prior to registration
Measured or calculated creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2, or
Serum creatinine =< 1.5 x institutional upper limit of normal (IULN), or a serum creatinine (SCr) based on age/gender as follows
Age < 13 maximum serum creatinine: Male 1.2 mg/dL; Female 1.2 mg/dL
Age 13 to < 16 maximum serum creatinine: Male 1.5 mg/dL; Female 1.4 mg/dL
Age 16-17 maximum serum creatinine: Male 1.7 mg/dL; Female 1.4 mg/dL
Total bilirubin =< 2 x IULN (must be documented within 28 days prior to registration for adults [age 18 or older]; must be documented within 14 days prior to registration for pediatric patients [age 12-17])
Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x IULN (must be documented within 28 days prior to registration for adults [age 18 or older]; must be documented within 14 days prior to registration for pediatric patients [age 12-17])
Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
Patients must have an echocardiogram (ECHO), multigated acquisition (MUGA), or functional cardiac imaging scan with a left ventricular ejection (LVEF) fraction >= 50% or a shortening fraction of >= 27%
For adults (age 18 or older), the ECHO or MUGA be performed within 42 days prior to registration
For pediatric patients (age 12-17), the ECHO, MUGA, or functional cardiac imaging scan must be performed within 14 days prior to registration
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable or unquantifiable viral load within 6 months prior to registration are eligible for this trial
Patients must not have known active hepatitis B (HBV) or hepatitis C virus (HCV) at date of registration. Patients with previously treated HBV or HCV that have an undetectable viral load and no residual hepatic impairment are eligible
Patients must not have any known central nervous system lymphoma
Patients must not have a history of or active interstitial pneumonitis or interstitial lung disease
Patients must not have had a diagnosis of inherited or acquired immunodeficiency
Patients must not have any known uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, hemodynamically unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Patients must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to registration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued prior to cycle 1, day 1
Patients with peripheral neuropathy must have < grade 2 at date of registration
Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, immunosuppressive drugs, or corticosteroids with doses higher than prednisone 10 mg or equivalent). Autoimmune diseases include but are not limited to autoimmune hepatitis, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), as well as symptomatic disease (e.g.: rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's granulomatosis]); central nervous system (CNS) or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis, multiple sclerosis or glomerulonephritis). Vitiligo, alopecia, hypothyroidism on stable doses of thyroid replacement therapy, psoriasis not requiring systemic therapy within the past 2 years are permitted
No second prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer, any in situ cancer or other cancer for which the patient has been disease free for two years
Females of childbearing potential must not be pregnant or nursing, and have a negative pregnancy test within 28 days prior to registration. Women/men of reproductive potential must have agreed to use an effective contraceptive method while receiving study drug and for women until 6 months after receiving the last dose of study drug or, for men, until 7 months after receiving the last dose of study drug. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
Patients must have sufficient diagnostic tissue specimens collected prior to registration
Patients must be offered participation in banking for planned translational medicine and future research. With patient consent, any residuals from the mandatory tissue submission will also be banked for future research
Patients who can complete patient-reported outcome instruments in English, Spanish, or French must complete the PROMIS Fatigue, the FACT/GOG-Ntx, and the PROMIS Global prior to registration and must agree to complete these instruments and the PRO-CTCAE or Pediatric PRO-CTCAE at the scheduled on-study assessment timepoints
Patients must be informed of the investigational nature of this study and all patients and/or their parents or legal guardians (for patients < 18 years of age) must sign and give written informed consent and assent (where appropriate) in accordance with institutional and federal guidelines
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name
Edit Delete

Annotated by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet